Safety and efficacy of catheter directed thrombolysis (CDT) in elderly with pulmonary embolism (PE)

Eneida Harrison,1 Jin Sun Kim,2 Vladimir Lakhter,3 Ka U Lio,4 Rami Alashram,1 Huaqing Zhao,5 Rohit Gupta,6 Maulin Patel 6, 6 James Harrison,7 Joseph Panaro,8 Kerry Mohrien,9 Riyaz Bashir,3 Gary Cohen,8 Gerard Criner,1 Parth Rali1

ABSTRACT

Introduction Acute pulmonary embolism (PE) remains a common cause for morbidity and mortality in patients over 65 years. Given the increased risk of bleeding in the elderly population with the use of systemic thrombolysis, catheter-directed therapy (CDT) is being increasingly used for the treatment of submassive PE. Nevertheless, the safety of CDT in the elderly population is not well studied. We, therefore, aimed to evaluate the safety of CDT in our elderly patients.

Methods We conducted a retrospective observational study of consecutive patients aged ≥65 years with a diagnosis of PE from our Pulmonary Embolism Response Team database. We compared the treatment outcomes of CDT versus anticoagulation (AC) in elderly. Propensity score matching was used to construct two matched cohorts for final outcomes analysis.

Results Of 346 patients with acute PE, 138 were ≥65 years, and of these, 18 were treated with CDT. Unmatched comparison between CDT and AC cohorts demonstrated similar in-hospital mortality (11.1% vs 5.6%, p=0.37) and length of stay (LOS) (3.81 vs 5.02 days, p=0.5395), respectively. The results from the propensity-matched cohort mirrored results of the unmatched cohort with no significant difference between CDT and AC in hospital mortality (11.8% vs 5.9%, p=0.545) or median LOS (3.76 vs 4.21 days, p=0.77), respectively.

Conclusion In this observational study using propensity score-matched analysis, we found that patients ≥65 years who were treated with CDT for management of acute PE had similar mortality and LOS compared with those treated with AC. Further studies are required to confirm these findings.

INTRODUCTION

Elderly patients aged ≥65 years are at an increased risk for pulmonary embolism (PE) and also have high mortality rates and bleeding risk after systemic anticoagulation (AC) compared with younger patients.1-3 Moreover, treatment with systemic thrombolysis is associated with higher risk of major bleeding (13% vs 3%) and intracranial haemorrhage (1.4% vs 0.5%).4-6 Catheter-directed thrombolysis (CDT) is an effective method of treatment of intermediate-risk PE with a rapid reduction in right ventricle (RV) to left ventricle ratio and mean pulmonary artery systolic pressure with an excellent safety profile in relatively younger cohort.7-10 In this observational study, we evaluated the safety of CDT therapy in the elderly cohort compared with standard AC first with univariate analysis and then using propensity score matching. We hypothesise that CDT therapy is not inferior in safety (bleeding risk, mortality) compared with that of AC in elderly cohort.

METHODS

We retrospectively reviewed the data of 346 consecutive patients with acute PE collected from September 2017 to June 2019 in the Temple University Hospital Pulmonary Embolism Response Team (PERT) registry with approved review board protocol 26021. We then selected all patients aged ≥65 years and excluded patients who underwent systemic thrombolysis, mechanical and surgical embolectomy. We then compared the clinical outcomes of patients treated with CDT.
to those treated with AC therapy with univariate analysis and then with propensity matching.

The treatment decision to proceed with CDT or other interventions was made by a multidisciplinary PERT. Major bleeding was evaluated and defined using the International Society on Thrombosis and Hemostasis (ISTH) criteria.11 The clinical outcomes included in-hospital mortality and hospital length of stay (LOS).

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Statistical analysis
Descriptive summary statistics are presented as mean values with SD for continuous variables and frequencies with percentages for categorical variables. Baseline characteristics were compared between the elderly CDT and AC cohorts using an independent two-sample t test or two-sample Wilcoxon rank-sum test for continuous variables and using a Pearson $\chi^2$ test for categorical variables.

Clinical characteristics that were evaluated include age, race, body mass index (BMI), history of hypothyroidism, deep vein thrombosis (DVT), PE, malignancy, diabetes mellitus, chronic obstructive pulmonary disease, cardiopulmonary disease, recent surgery, current use of AC prior to admission, inferior vena cava filter, chronic kidney disease with and without need for renal replacement therapy, and PE severity by European Society of Cardiology (ESC) classification as low risk (1), intermediate-to-low risk (2), intermediate-to-high risk and high risk (4).4 There were two outcomes of interest: (1) in-hospital mortality and (2) LOS. The LOS was not censored for in-hospital mortality.

The association between patient characteristics and outcome was assessed using univariate logistic regression with OR and corresponding 95% CIs.

We used propensity scores to construct two matched groups for comparative outcomes analysis. In order to perform propensity scores matching, we excluded patients who had history of malignancy or recent surgery and patients who had a PE severity as defined by ESC classification of low risk (1), intermediate-to low risk (2) and high risk (4).

For outcome analysis, we compared elderly patients treated with CDT versus AC. Statistical analyses were conducted using Stata (V. 14.0).

| Table 1 | Baseline patient characteristics, univariate analysis and propensity matched groups |
|---------|----------------------------------------------------------------------------------|
| Column  | Unmatched groups | Propensity matched groups |
|         | AC 108           | CDT 18          | P value | AC 17   | CDT 17 | P value |
| Age     | 75.5±7.99        | 73.8±6.19       | 0.329   | 77.6±7.89 | 73.7±6.35 | 0.121 |
| Caucasian | 19 (41.7%)     | 5 (27.8%)       | 0.464   | 2 (11.7%) | 5 (29.4%) | 0.286 |
| BMI (kg/m$^2$) | 28.8±8.51 | 33.8±7.66       | 0.024   | 30.4±12.2 | 33.9±7.9  | 0.340 |
| Medical History |
| Hypothyroidism | 12 (11.2%) | 3 (16.7%) | 0.51 | 1 (5.9%) | 3 (17.7%) | 0.287 |
| DVT     | 15 (14.0%)       | 6 (33.3%)       | 0.043   | 4 (23.5%) | 6 (35.3%) | 0.452 |
| PE      | 10 (9.4%)        | 5 (29.4%)       | 0.018   | 1 (5.9%) | 5 (29.4%) | 0.072 |
| Malignancy | 33 (30.8%)     | 0               | 0.006   | –        | –        | –     |
| Diabetes mellitus | 39 (36.5%) | 3 (16.7%) | 0.1 | 7 (41.2%) | 3 (17.6%) | 0.132 |
| COPD    | 29 (27.4%)       | 2 (11.1%)       | 0.141   | 6 (35.3%) | 1 (5.9)  | 0.034 |
| Cardiopulmonary | 46 (55.4%) | 8 (53.3%) | 0.881 | 8 (66.7%) | 7 (50.0%) | 0.391 |
| Recent surgery | 23 (21.5%) | 0 | 0.029 | – | – | – |
| AC use  | 11 (10.3)        | 1 (5.6%)        | 0.529   | 2 (11.8%) | 1 (5.9%)  | 0.545 |
| IVC filter | 3 (2.8%)       | 2 (11.1%)       | 0.096   | 1 (5.9%) | 2 (11.8%) | 0.545 |
| CKD     | 17 (15.9%)       | 2 (11.1%)       | 0.601   | 3 (17.7%) | 2 (11.8%) | 0.628 |
| ESRD on RRT | 4 (3.7%)     | 0               | 0.404   | 1 (5.9%) | 0        | 0.31 |
| PE severity (ESC) |
| 1       | 23 (21.5%)       | 0               | <0.001  | 0        | 0        | –     |
| 2       | 43 (40.2%)       | 0               | 0       | 0        | 0        | –     |
| 3       | 38 (35.5%)       | 18 (100%)       | 17(100%) | 17(100%) | 0        | 0     |
| 4       | 3 (2.8%)         | 0               | 0       | 0        | 0        | 0     |

Bold font indicates statistical significance

AC, anticoagulation; BMI, body mass index; CDT, catheter directed thrombolysis; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; ESC, European Society of Cardiology; ESRD, end-stage renal disease; IVC, inferior vena cava; PE, Pulmonary embolism; RRT, renal replacement therapy.
RESULTS

We identified 138 (39.9%) patients who were 65 years and older out of the 346 consecutive patients in the PERT database. The mean (SD) age was 75.3 (7.2) years, 56.5% were females, 19% were Caucasian. Among those identified, 108 (85.7%) patients were treated with AC and 18 patients (14.3%) with CDT. Baseline clinical characteristics of the patients are shown in table 1.

All 18 patients in the CDT cohort had intermediate-to-high risk (3) PE as compared with 38.7% of patients in the non-CDT cohort (p<0.001). Baseline clinical characteristics of the CDT cohort are shown in table 2. The overall mortality in the elderly cohort was 6.3%. All-cause mortality in CDT compared with AC cohorts was 11.1% and 5.6% respectively (p=0.37).

Univariate analysis of clinical characteristics showed that patients treated with CDT compared with AC had significant comorbidities including BMI (28.8 vs 33.8, p=0.024), histories of DVT (14% vs 33.3%, p=0.043), PE (9.4% vs 29.4%, p=0.018) or malignancy (30.8% vs 0%, p=0.006), recent surgery (21.5% vs 0%, p=0.029) and PE severity score (p<0.001) (table 1).

In-hospital mortality was not different in the CDT cohort compared with the AC cohort (OR (95% CI) 2.15 (0.394 to 11.457), p=0.381). The median LOS for the CDT vs AC cohort were 3.81 and 5.02 days respectively (p=0.540).

Baseline characteristics for the propensity-matched cohort are listed in table 1 and show no significant differences between the two groups, suggesting good-quality match.

The results in the propensity-matched cohort showed no difference for in-hospital mortality for the CDT group (5.88% vs 11.76%, p=0.545). Additionally, the median

Table 2 Clinical descriptions of patients receiving CDT

| Age  | Gender | Admission oxygen requirement | PE category (ESC) Classification | DVT | CDT* | Survival to discharge | ISTH major bleeding | Discharge location |
|------|--------|------------------------------|----------------------------------|-----|------|-----------------------|---------------------|--------------------|
| 78   | Female | BIPAP                        | Intermediate high                | No  | Bilateral 12 mg       | Yes                  | Yes                 | SNF                |
| 75   | Female | NRB                          | Intermediate high                | Yes | Bilateral 16 mg       | No                   | No                  | Home               |
| 84   | Female | 4 L/min                      | Intermediate high                | Yes | Unilateral 20 mg      | Yes                  | No                  | SNF                |
| 79   | Female | 6 L/min                      | Intermediate high                | Yes | Bilateral 12 mg       | Yes                  | No                  | Home               |
| 77   | Female | 10 L/min                     | Intermediate high                | No  | Unilateral 6 mg       | Yes                  | No                  | Home               |
| 73   | Male   | 6 L/min                      | Intermediate high                | Yes | Bilateral; 12 mg      | Yes                  | No                  | Home               |
| 73   | Female | 4 L/min                      | Intermediate high                | Yes | Bilateral 12 mg       | Yes                  | No                  | Home               |
| 69   | Female | 0 L/min                      | Intermediate high                | Yes | Bilateral 12 mg       | Yes                  | No                  | Home               |
| 68   | Female | 0 L/min                      | Intermediate high                | No  | Bilateral 12 mg       | No                   | No                  | Home               |
| 67   | Male   | 0 L/min                      | Intermediate high                | Yes | Bilateral 24 mg       | Yes                  | No                  | Home               |
| 66   | Male   | 0 L/min                      | Intermediate high                | No  | Bilateral 24 mg       | Yes                  | No                  | Home               |
| 65   | Male   | 0 L/min                      | Intermediate high                | –   | Bilateral 24 mg       | Yes                  | No                  | Home               |
| 66   | Female | 2 L/min                      | Intermediate high                | Yes | Bilateral 12 mg       | Yes                  | No                  | Home               |
| 71   | Male   | 2 L/min                      | Intermediate high                | Yes | Bilateral 12 mg       | Yes                  | No                  | Home               |
| 76   | Male   | 3 L/min                      | Intermediate high                | Yes | Bilateral 24 mg       | Yes                  | No                  | Home               |
| 76   | Female | 0 L/min                      | Intermediate high                | No  | Bilateral 12 mg       | Yes                  | No                  | SNF                |
| 83   | Male   | 2 L/min                      | Intermediate high                | No  | Bilateral 12 mg       | No                   | No                  | Deceased           |
| 83   | Male   | 2 L/min                      | Intermediate high                | No  | Bilateral 12 mg       | Yes                  | No                  | SNF                |

*CDT details: unilateral versus bilateral catheter placement in the pulmonary artery catheters and total tPA dose.

BIPAP, bilevel positive airway pressure; CDT, catheter directed thrombolysis; DVT, deep vein thrombosis; ESC, European Society of Cardiology; ISTH, International Society on Thrombosis and Hemostasis; NRB, non-rebreather; PE, pulmonary embolism; SNF, skilled nursing facility; tPA, tissue plasminogen activator.

Table 3 Bleeding complication, survival and follow-up for patients receiving CDT

| CDT discharge outcome | n (%) |
|-----------------------|-------|
| Bleeding after tPA*   | 1 (5.6) |
| Gastrointestinal bleed| 1 (5.6) |
| Survival at discharge | 16 (88.9) |
| Outpatient follow-up† | 12 (66.7) |
| Death from any cause within 30 days | 2 (11.1) |
| Rehospitalisation within 30 days | 0 |
| Supplemental oxygen therapy at discharge | 1 (5.6) |

*Major bleeding was evaluated and defined using the International Society on Thrombosis and Hemostasis criteria.
†Four patient were outside referrals and followed up at their respective institutions.
CDT, catheter directed therapy; tPA, tissue plasminogen activator.

All 18 patients in the CDT cohort had intermediate-to-high risk (3) PE as compared with 38.7% of patients in the non-CDT cohort (p<0.001). Baseline clinical characteristics of the CDT cohort are shown in table 2. The overall mortality in the elderly cohort was 6.3%. All-cause mortality in CDT compared with AC cohorts was 11.1% and 5.6% respectively (p=0.37).

Univariate analysis of clinical characteristics showed that patients treated with CDT compared with AC had significant comorbidities including BMI (28.8 vs 33.8, p=0.024), histories of DVT (14% vs 33.3%, p=0.043), PE (9.4% vs 29.4%, p=0.018) or malignancy (30.8% vs 0%, p=0.006), recent surgery (21.5% vs 0%, p=0.029) and PE severity score (p<0.001) (table 1).

In-hospital mortality was not different in the CDT cohort compared with the AC cohort (OR (95% CI) 2.15 (0.394 to 11.457), p=0.381). The median LOS for the CDT vs AC cohort were 3.81 and 5.02 days respectively (p=0.540).

Baseline characteristics for the propensity-matched cohort are listed in table 1 and show no significant differences between the two groups, suggesting good-quality match.

The results in the propensity-matched cohort showed no difference for in-hospital mortality for the CDT group (5.88% vs 11.76%, p=0.545). Additionally, the median
LOS for the CDT versus AC cohort were 3.76 and 4.21 days (p=0.77) after matching. Postprocedure adverse effect and outpatient follow-up information listed in table 3.

**DISCUSSION**

In this study, elderly patients with mean age of 75 years with intermediate-risk PE were treated with CDT as compared with systemic AC. The CDT cohort had significantly higher comorbidities including BMI, histories of DVT, PE or malignancy, recent surgery and PE severity scores. Even with a more moribund patient population, there was no statistically significant difference when comparing in-hospital mortality (p=0.545) and LOS (p=0.77) among the two cohorts after propensity matching. There were two major bleeding events per ISTH criteria and two fatalities in the CDT cohort but all-cause mortality in CDT compared with AC cohorts was not statistically significant.

Optimal management remains uncertain for elderly patients ≥65 years as they have a higher 30-day and 90-day mortality rates of 14.2% and 20.8%, respectively, as well as higher risk of bleeding compared with younger patients (2.5% vs 0.9%).1356

Systemic thrombolysis is another intervention that is under investigation but is not recommended in the management of intermediate risk PE because the risk of life-threatening bleeding complications outweighs the benefits of therapy.412 The PEITHO trial is a large randomised control trial that found increased risk of major bleeding in a nonelderly cohort which offsets the benefits of therapy.5 A subgroup analysis of patients older than 65 years old had higher risk of bleeding events (12.93% vs 4.10%, p<0.001). There is limited published data on treatment options and associated morbidity and mortality for elderly patients with intermediate-risk PE using CDT therapy.

The mean age for our CDT cohort was 75 years whereas the average age in published clinical trials from ULTIMA, SEATTLE II, PERFECT and OPTALYSE were 59–65 years.710 In our CDT cohort, 10 patients (55.6%) were treated with total tissue plasminogen activator (tPA) dose of 12mg. The remaining eight patients were treated with variable total doses ranging from 6 to 24 mg. The ULTIMA trial infused 10mg of tPA per lung and SEATTLE II infused 24mg tPA.78 The OPTALYSE trial had different regimens including 4mg for 2 hours, 4mg for 4 hours, 6mg for 6 hours and 12mg for 6 hours. Reported bleeding rates in published literature with CDT studies include up to 10% and ours was 5.6%.7810 Each study used a different definition of bleeding.7410

We had two patient deaths that occurred 24 hours post-CDT procedure. In-hospital death for ULTIMA, SETTLE II and OPTALYSE trials are zero, three patients and one patient, respectively.7810 All these trials enrolled both low-risk PES and high-to-intermediate risk PES, while our study only included high-intermediate risk PES.

The patient who experienced major bleeding in our CDT cohort was a 78-year-old woman who developed a diverticular bleed post-treatment that required transfusions and self-resolved without intervention.

Out of the two patients who expired, one was a 75-year-old woman that developed massive haemoptysis from right lower lobe pulmonary artery rupture likely predisposed by her history of chronically elevated haemidiaphragm 3 hours after catheter placement.15 The other patient was an 83-year-old man who underwent CDT with a total tPA dose of 12mg administered over 6 hours who deteriorated and subsequently had pulseless electrical activity arrest.

In our study, patients who survived were asymptomatic and had minimal oxygen dependence postprocedure with 15 out of 18 patients being oxygen-free at discharge. Most patients were discharged to home and had no 30-day readmission. At the follow-up, patients remained oxygen-free and had overall good functional status. Overall, there was greater than 95% survival rate with associated clinical improvement.

Some strengths of our study include collecting data on a patient cohort who are generally sicker with increased comorbidities. We demonstrate robust statistical matching using propensity score-matched analysis and univariate analysis for comparison between cohorts. A rapid assessment of patients by a PERT team is critical in elderly patients with acute PE. AC is the cornerstone management of these patients; however, if deterioration occurs despite AC therapy, CDT is a relatively safe and effective approach that rapidly restores RV function. We hope that multicentre cohort studies from high-volume centres will allow for more reliable conclusions on the efficacy of CDT in treating acute PE in the elderly. Our results must be interpreted in context of the study limitations including a small size and retrospective data from a single academic tertiary medical centre.

**CONCLUSION**

This retrospective observational study shows that elderly patients have similar in-hospital mortality and LOS when treated with CDT versus anticoagulation alone. In elderly patients who have high-to-intermediate risk acute PE and are candidates for interventional therapy, CDT may be a safe alternative treatment modality. These findings will need to be confirmed in randomised controlled trial like Pulmonary Embolism Thrombus Removal With Adjunct Catheter-Directed Therapy (PE-TRACT) trial.

**Author affiliations**

1Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA
2Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA
3Cardiology, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA

**Copyright**
Contributors EH is the primary author, collected the data and is the guarantor of the article, taking responsibility for the integrity of the work as a whole from inception to published article. RA, MP, JSK collected the data. VL, KUL, RG, JH, KM, PR and GC helped write the manuscript. HZ conducted the statistical analysis. JP, RB, GC reviewed the imaging studies and also treated the patients who underwent catheter directed thrombolysis. JSK was a secondary coauthor, responsible for the study concept and helped write the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Our PERT database has deidentified participant data that can be available on reasonable request from Eneida Harrison ORCID ID 0000-0001-7628-3500.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Maulin Patel http://orcid.org/0000-0002-7432-7255

REFERENCES
1. Bauersachs RM. Use of anticoagulants in elderly patients. Thromb Res 2012;129:107–15.
2. Tritscher T, Auesky D. Venous thromboembolism in the elderly: a narrative review. Thromb Res 2017;155:140–7.
3. Polo Friz H, Molteni M, Del Sorbo D, et al. Mortality at 30 and 90 days in elderly patients with pulmonary embolism: a retrospective cohort study. Intern Emerg Med 2015;10:431–6.
4. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020;41:543–603.
5. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med Overseas Ed 2014;370:1402–11.
6. Eberle H, Lyn R, Knight T, et al. Clinical update on thrombolytic use in pulmonary embolism: a focus on intermediate-risk patients. Am J Health Syst Pharm 2018;75:1275–85.
7. Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014;129:479–86.
8. Piazza G, Hohlfelder B, Jaff MR, et al. A prospective, single-arm, multicenter trial of Ultrasound-Facilitated, Catheter-Directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the Seattle II study. JACC Cardiovasc Interv 2015;8:1382–92.
9. Kuo WT, Banerjee A, Kim PS, et al. Pulmonary embolism response to fragmentation, embolectomy, and catheter thrombolysis (perfect). Chest 2015;148:667–73.
10. Tapson VF, Sterling K, Jones N, et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial. JACC Cardiovasc Interv 2018;11:1401–10.
11. Kaatz S, Ahmad D, Spyropoulos AC, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015;13:2119–26.
12. Kearon C, Akl EA, Ornelas J. Antithrombotic therapy for VTE disease: chest guideline and expert panel report. Chest 2016;149:315–52.
13. Fernandez Romero G, Riyaz B, Gupta R, et al. Pulmonary artery rupture after ultrasound-assisted Catheter-directed thrombolysis. Am J Respir Crit Care Med 2019;199:e30–2.